Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Taxotere: Clinical Trials in Non-Small Cell Lung Cancer.

Ornstein1, Rigas

  • 1Thoracic Oncology Program, Norris Cotton Cancer Center, Section of Hematology/Oncology; Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, 03756-0001, USA.

The Oncologist
|July 1, 1999
PubMed
Summary

Docetaxel shows significant antitumor activity in advanced non-small cell lung cancer (NSCLC) patients. This chemotherapy agent offers improved response rates in both chemotherapy-naive and previously treated NSCLC individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Structure of Adsorbed CO(2) in Slitlike Micropores at Low and High Temperature and the Resulting Micropore Size Distribution Based on GCMC Simulations.

Journal of colloid and interface science·2000
Same author

Arterial Thrombosis in Ulcerative Colitis: Case Report.

The International journal of angiology : official publication of the International College of Angiology, Inc·1998
See all related articles

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Cisplatin-based chemotherapy provided limited survival benefits for advanced non-small cell lung cancer (NSCLC) in the 1980s.
  • Docetaxel, a potent microtubule-stabilizing agent, demonstrated preclinical advantages over paclitaxel, warranting clinical investigation.

Purpose of the Study:

  • To evaluate the efficacy and safety of docetaxel as a single agent in patients with advanced or recurrent NSCLC.
  • To assess docetaxel's activity in both chemotherapy-naive and platinum-refractory NSCLC populations.

Main Methods:

  • Seven Phase II clinical trials involving 328 patients with advanced or recurrent NSCLC.
  • Docetaxel administered at 100 mg/m² intravenously every 21 days.
  • Separate cohorts for 160 chemotherapy-naive patients and 168 patients with prior platinum-based chemotherapy failure.

Related Experiment Videos

Main Results:

  • Antitumor response rates were 27% in chemotherapy-naive patients and 17% in platinum-treated patients.
  • Median survival time was 9.2 months for chemotherapy-naive patients.
  • Common adverse events included alopecia, fluid retention, infusion reactions, leukopenia, onycholysis, and rash; dexamethasone premedication mitigated some toxicities.

Conclusions:

  • Docetaxel exhibits significant antitumor activity in both chemotherapy-naive and platinum-treated patients with advanced or recurrent NSCLC.
  • Ongoing trials are investigating docetaxel in combination regimens and as primary therapy for Stage III NSCLC.